Indeed, blocking IL-1 signaling with monoclonal antibodies targeting the interleukin 1 receptor accessory protein (IL1RAP and IL1R3) has been shown to have an antileukemic effect on CML and AML cells in vivo [27,28]. Here, IL1RAP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.